Sutro Biopharma, Inc. (STRO)

Sutro Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-106.79	-119.2	-105.54	-32.13	-55.74
Depreciation & Amortization	10.44	8.29	9.77	4.3	4.78
Share-Based Compensation	24.91	26.3	23.24	11.92	10.31
Other Operating Activities	-40.18	88.16	-9.16	-51.89	-24.37
Operating Cash Flow	-111.62	3.55	-81.68	-67.8	-65.02
Capital Expenditures	-4.32	-7.86	-15.32	-7.13	-3.48
Acquisitions	0	0.01	0.01	0.09	0
Change in Investments	0.39	-27.17	-82	7.64	-47.65
Investing Cash Flow	-3.92	-35.02	-97.32	0.6	-51.13
Share Issuance / Repurchase	14.34	58.15	4.24	254.56	1.11
Debt Issued / Paid	123.71	-9.38	0	15	-5
Other Financing Activities	-0.49	-0.46	-0.99	-0.31	-0.3
Financing Cash Flow	137.55	48.31	3.26	269.25	-4.18
Net Cash Flow	22.01	16.84	-175.74	202.05	-120.34
Free Cash Flow	-115.93	-4.31	-97	-74.93	-68.5
Free Cash Flow Margin	-75.41%	-6.36%	-156.76%	-175.39%	-160.30%
Free Cash Flow Per Share	-1.93	-0.09	-2.10	-2.30	-2.98

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).